Sofpironium Topical Gel - A Comprehensive Overview

Overview

The use of topical Sofpironium gel has been investigated for managing primary axillary hyperhidrosis (PAH). According to clinical investigations, Sofpironium gel works well to lessen sweating and lessen the intensity of symptoms associated with hyperhidrosis. On June 20th, 2024, the United States Food and Drug Administration approved Sofpironium topical gel for primary axillary hyperhidrosis.

Drug Group:

The Sofpironium topical gel is a member of the anticholinergic medication class. Acetylcholine is a neurotransmitter that is involved in sweat production, and anticholinergics function by inhibiting its activity. Sofpironium lessens excessive sweating in diseases like primary axillary hyperhidrosis (PAH) by blocking the effect of acetylcholine. It is a topical remedy for people who sweat excessively under their arms.

Dosages:

Sofpironium 12.4 percent (w/w) in a 50 (milliliters) vial with an applicator and metered dosing pump. In 0.67 mL of gel, one complete pump provides 72 mg(milligrams) of Sofpironium.

The Sofpironium topical gel comes in a bottle with an applicator, cap, and multi-dose metered pump. Each container has a multi-dose pump that can dispense 60 pump actuation and hold 50 mL (milliliters) of gel. Each pump action dispenses 0.67 mL of gel.

For Patients:

What Is Primary Axillary Hyperhidrosis?

The hallmark sign of primary axillary hyperhidrosis is profuse underarm sweat, unrelated to another medical condition. It is a long-term illness that usually first manifests in youth or early adulthood and affects both men and women. The exact etiology of primary axillary hyperhidrosis is not known, but it appears to be associated with overactive sweat glands and sympathetic nervous system activation of the glands. This illness can have a serious negative effect on a person's quality of life by adding discomfort, emotional suffering, and social shame.

What Is the Management of Primary Axillary Hyperhidrosis?

There are several therapy options available for the management of primary axillary hyperhidrosis. As first-line therapy, topical medications such as antiperspirants with aluminum or zirconium salts are frequently advised. Other methods include iontophoresis, oral drugs such as anticholinergics, and botulinum toxin injections if topical therapies prove ineffective. Suction curettage and sympathetic denervation are two surgical procedures that might be explored in severe situations that do not improve with conventional medicines. Individualizing the treatment plan according to the requirements and preferences of the patient is crucial.

How Does Sofpironium Topical Gel Work?

Sofpironium topical gel blocks M3 muscarinic receptor activity in the eccrine sweat glands at the application site. This inhibition lessens sweat production, which relieves the discomfort of excessive perspiration. A topical anticholinergic drug called Sofpironium is made especially to target the sweat glands and reduce systemic absorption, which lowers the possibility of systemic side effects. Sofpironium efficiently lowers sweat production and aids in the management of disorders like primary axillary hyperhidrosis by inhibiting the muscarinic receptors.

What Are the Clinical Applications of Using Sofpironium Topical Gel?

The main indication for Sofpironium topical gel is the treatment of primary axillary hyperhidrosis, or excessive perspiration under the arms, in adults and children nine years of age and older. It has been demonstrated to lower sweat production and lessen symptoms in those suffering from this illness. Sofpironium gel decreases systemic absorption and targets sweat glands, lowering the possibility of systemic side effects. This topical anticholinergic drug inhibits the application site's eccrine sweat glands' M3 muscarinic receptors.

What Precautions Are Needed Before Taking Sofpironium Topical Gel?

Patients should disclose all allergies to their doctor before using Sofpironium topical gel for primary axillary hyperhidrosis, particularly if they are allergic to Sofpironium or other anticholinergic drugs. To avoid any possible drug interactions, they should also let their doctor know about all other medications they are taking, including prescription, over-the-counter, and herbal supplements. All medical issues should be disclosed by the patient, particularly if there are any skin disorders or infections at the application location. To safely and efficiently administer Sofpironium topical gel, patients should present a thorough medical history to the physician.

What Are the Side Effects of Using Sofpironium Topical Gel?

• Dry mouth.

• Blurred vision.

• Pain, redness, irritation, and itching in underarm areas.

• Mydriasis (dilation of eye pupils).

• Urination problem.

For Doctors:

Description:

Sofpironium topical gel is an anticholinergic drug. The drug compound known as Sofpironium bromide is a white to off-white powder with the chemical formula 3'(R)-[2(R) cyclopentylphenylhydroxy-acetoxy]. The chemical formula of -1'-methyl-1'-ethoxycarbonylmethyl-pyrrolidinium bromide is C22H32BrNO5, and it has a molecular weight of 470.4 g/mol (gram per mole).

It is highly soluble in chloroform and freely in water, ethanol, acetonitrile, and methanol. In an airless bottle sealed with a multi-dose metered pump, Sofpironium topical gel is a clear to translucent, colorless to pale yellow viscous gel containing 12.45 percent (w/w) weight by weight Sofpironium (equal to 15 percent Sofpironium bromide). 72 mg of Sofpironium, or 87 mg of Sofpironium bromide, are delivered by each pump in 0.67 mL of gel. Citric acid, 77.2 percent v/v dehydrated alcohol, hexylene glycol, hydroxypropyl cellulose, and isopropyl myristate are the inactive components.

Therapeutic Uses of Sofpironium Topical Gel:

• Primary Axillary Hyperhidrosis: This condition causes excessive perspiration in the underarms, which can be treated with Sofpironium topical gel.

• Clozapine-Induced Hypersalivation: Patients with treatment-resistant schizophrenia who are receiving Clozapine have shown improved results when using Sofpironium topical gel.

• Secondary Hyperhidrosis: Sofpironium topical gel has successfully treated secondary hyperhidrosis in patients with severe Duchenne muscular dystrophy (DMD).

Indications:

An anticholinergic called Sofpironium topical gel treats primary axillary hyperhidrosis in adults and children nine years and older.

Contraindications:

Glaucoma, paralytic ileus, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, myasthenia gravis, and Sjögren's syndrome are among the medical conditions for which Sofpironium topical gel is contraindicated.

Warnings and Precautions:

1. Urinary Retention

When treating patients with a history of or current documentation of urinary retention, use Sofpironium topical gel cautiously. Prescribers and patients should monitor urinary retention symptoms, such as difficulties passing pee or a swollen bladder, equally, particularly in those who have prostatic hypertrophy or bladder-neck obstruction. Stop using the product immediately and see a doctor if any warning signs or symptoms appear.

2. Regulation of Body Temperature:

When anticholinergic medications, such as Sofpironium topical gel, are taken in an environment with high temperatures, heat illness (hyperpyrexia and heat stroke due to decreased sweating) may result. In hot or extremely warm weather, look for a general lack of perspiration and refrain from taking Sofpironium topical gel if individuals are not perspiring.

3. Using an Automobile or Machinery:

When using Sofpironium topical gel, temporary blurriness of vision may occur. If the individuals experience blurred vision, stop using the product and refrain from doing tasks that call for clear eyesight, such as operating machinery, driving a car, or performing dangerous tasks, until the symptoms go away.

What Are the Adverse Reactions of Sofpironium Topical Gel?

• Application site dermatitis.

• Nasopharyngitis.

• Erythema.

• Pruritus.

• Dry mouth.

• Oropharyngeal pain.

• Headache.

• Urinary hesitation.

• Blurred vision.

• Nasal dryness.

• Dry eyes.

• Dry skin.

• Constipation.

• Hypersalivation.

What Are the Pharmacological Aspects of Sofpironium Topical Gel?

Mechanism of Action:

Sweat glands and other peripheral tissues have acetylcholine receptors, which are competitively inhibited by Sofpironium bromide. Sofpironium bromide inhibits the stimulation of these receptors, which indirectly lowers the rate of sweating.

Pharmacodynamics:

It has been observed that Sofpironium topical gel has no clinically significant effect on QTc interval prolongation, even at exposures three times higher than the maximum recommended dose.

Pharmacokinetics:

On the other hand, a study that included adults and pediatric patients aged 10 to 17 years assessed the pharmacokinetic properties of Sofpironium gel after topical application to the axillae. According to the study, adults and pediatric patients reached peak plasma concentrations of Sofpironium at a median of one hour and 1.5 hours, respectively.

Peak plasma values ranged from 0.07 to 0.08 ng/mL on average. Notably, the pharmacokinetic parameters recorded may vary from systemic absorption and were obtained following topical treatment. More research may be required to comprehend the pharmacokinetics of Sofpironium topical gel completely.

Drug Interactions:

• Abiraterone.

• Aclidinium.

• Amisulpride.

• Anticholinergic/sedative combos.

• Atropine.

• Atropine IV/IM.

• Benztropine.

• Brompheniramine.

• Bupropion.

• Carbinoxamine.

• Chlorpheniramine.

• Chlorpromazine.

• Cinacalcet.

• Clemastine.

• Cocaine topical.

• Cyclizine.

• Cyproheptadine.

• Dacomitinib.

• Darifenacin.

• Darunavir.

• Dexchlorpheniramine.

• Dicyclomine.

• Diphenhydramine.

• Droperidol.

• Fesoterodine.

• Fluoxetine.

• Fluphenazine.

• Glycopyrrolate.

• Glycopyrrolate inhaled.

• Glycopyrronium tosylate topical.

• Haloperidol.

• Hydroxyzine.

• Hyoscyamine.

• Hyoscyamine spray.

• Ipratropium.

• Lorcaserin.

• Loxapine.

• Loxapine inhaled.

• Meclizine.

• Mepenzolate.

• Methscopolamine.

• Miconazole oral.

• Mirabegron.

• Molindone.

• Nabilone.

• Paroxetine.

• Perphenazine.

• Pimozide.

• Prochlorperazine.

• Promethazine.

• Propantheline.

• Quinidine.

• Revefenacin.

• Ritonavir.

• Rolapitant.

• Scopolamine.

• Scopolamine intranasal.

• Solifenacin.

• Terbinafine.

• Thioridazine.

• Thiothixene.

• Tiotropium.

• Tipranavir.

• Tolterodine.

• Trifluoperazine.

• Trihexyphenidyl.

• Triprolidine.

• Trospium chloride.

• Umeclidinium bromide.

Use in Specific Populations:

Pregnancy: There is no precise information available regarding the usage of Sofpironium topical gel during pregnancy. Sofpironium gel's effectiveness and safety in pregnant patients have not been investigated.

Lactation: Data on Sofpironium or its metabolites in human milk, their effects on breastfed infants, or their impact on milk production are not currently available. Nonetheless, research on nursing rats has demonstrated that Sofpironium or its metabolites can enter the milk stream following subcutaneous delivery.

In addition to the mother's clinical need for Sofpironium and any potential adverse effects the medicine or the underlying maternal disease may have on the breastfed newborn, it is crucial to consider the developmental and health benefits of breastfeeding. More research is required to fully comprehend the effect of Sofpironium on breastfeeding.

Pediatrics: The safety, efficacy, and pharmacokinetics of Sofpironium for the treatment of primary axillary hyperhidrosis in pediatric patients nine years of age and older have been established. Data from 72 pediatric patients aged nine and older who participated in two multicenter trials support using Sofpironium in this age range. Nevertheless, Sofpironium 's efficacy and safety in juvenile patients under nine have not been proven.

Geriatrics: There were not enough participants in the Sofpironium clinical trials who were 65 or older to assess whether their responses differed from those of younger participants. According to other documented clinical experiences, there haven't been any changes in reactions between older and younger individuals.

Clinical Studies:

Numerous clinical studies have been conducted on Sofpironium topical gel to assess its effectiveness and safety in treating various illnesses. A topical anticholinergic medication called Sofpironium bromide gel was created to treat hyperhidrosis, a disorder marked by profuse perspiration. The main conclusions from these clinical investigations are outlined below:

Efforts to Treat Primary Axillary Hyperhidrosis (PAH)

Sofpironium bromide gel (5 percent) was approved for the first time in Japan in 2020. Sofpironium gel efficiently lowers sweating by blocking M3 muscarinic receptors in eccrine glands at application site one, according to clinical tests.

Efficacy in PAH

A phase III study in Japanese patients with PAH 2 showed the safety and effectiveness of Sofpironium gel. Roughly 50 percent of individuals with a Hyperhidrosis Disease Severity Scale (HDSS) score of three or four saw a clinically meaningful improvement after receiving Sofpironium for one week.

Long-Term Medication

In Japanese patients with PAH 3, a 52-week Sofpironium medication was assessed for safety and effectiveness over an extended period. According to the study, Sofpironium's effectiveness was sustained throughout the 52-week treatment, with 57 percent of patients reporting an HDSS score of one or two and a 50 percent or more significant decrease in sweat weight. During the investigation, no new safety concerns were found.

Treatment of Clozapine-Induced Hypersalivation:

Sofpironium gel has also been studied as a potential treatment for clozapine-induced hypersalivation in patients with treatment-resistant schizophrenia. According to research, Sofpironium gel was found to dramatically lower saliva volume in patients experiencing hypersalivation caused by Clozapine.